SCHEMBL21738951

SCHEMBL21738951

CC(C)(C)OC(=O)N1CC2CCC(C1)N2C1CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM1 P11229 1/20 0.50
CHRM3 P20309 1/20 0.50
HPGD P15428 1/20 0.45
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PREP P48147 4/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
GPR119 Q8TDV5 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18689670 0.93 CHRM2 (0.51) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL31584123 0.92 NR1H2 (0.48) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL32687783 0.86 NR1H2 (0.51) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL27456630 0.85 NR1H2 (0.50) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL14934008 0.85 NR1H2 (0.50) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL24582817 0.85 NR1H2 (0.44) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL31208756 0.84 HPGD (0.46) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL18211909 0.84 NR1H2 (0.49) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL18701831 0.82 CHRM2 (0.51) NR1H2CHRM2CHRM1CHRM3HPGD
SCHEMBL18764008 0.82 CHRM2 (0.51) NR1H2CHRM2CHRM1CHRM3HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187702-B2 Sulfonamideurea compounds INFLAZOME LIMITED (IE) 2025-01-07 US disclosed
US-20220194923-A1 NOVEL SULFONAMIDEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2022-06-23 US disclosed
US-20220194923-A1 NOVEL SULFONAMIDEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2022-06-23 US disclosed
CN-112672995-A Novel sulfonamide urea compounds 英夫拉索姆有限公司 2021-04-16 CN disclosed
WO-2020035464-A1 NOVEL SULFONAMIDEUREA COMPOUNDS INFLAZOME LIMITED (IE) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194923-A1 NOVEL SULFONAMIDEUREA COMPOUNDS NLRP3, NOD1, NLRP1 NR1H2 587/4885CHRM2 1570/4885CHRM1 1507/4885
US-12187702-B2 Sulfonamideurea compounds NLRP3, NOD1, NLRP1 NR1H2 363/4885CHRM2 1738/4885CHRM1 1677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.